PATENT CLAIM ANALYSIS

Application Number: 15782023
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "227100"]

Abstract:
The disclosure relates to the combined use of an immunotherapeutic composition comprising recombinant  Listeria  strains expressing a heterologous antigen fused to a truncated listeriolysin O (tLLO), a truncated ActA protein, or a PEST amino acid sequence and an antibiotic regimen, which may be sequentially administered in order to prevent the persistence, seeding of  Listeria  and/or formation of  Listeria  biofilms while allowing for an anti-tumor/anti-cancer or anti infectious disease immunotherapeutic response to take place. Disclosed are also methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering the above composition.

Claim (Index 7):
The method of any one of  claims 1 - 6 , wherein said antibiotic regimen comprises at least one of the following: clindamycin, gentamicin, azithromycin, vancomycin, phosphomycin, linezolid, rifampicin, minocycline, telithromycin, pefloxacin, a beta-lactam, fusidic acid, a macrolide, a fluoroquinolone, Meropenam Both, Moxifloxacin Both, ampicillin, dapzone, trimethoprim/sulfa (Bactrim) or any combination thereof.

Metadata:
- Claim Count in Document: 78.0
- Percentile: 94.0
- Lexical Diversity: 1.43243
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14204806', '14341215', '15119661', '14581217', '14383970']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7561731250320518
- 35 USC 102 Novelty (BERT): 0.5669111521178906
- Combined Prediction Score: 0.7372469277406357
- Mean Citation Score: 482.61735800000014
- Max Citation Score: 531.1218
- Similarity Product: 320.52732557437423

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test